Erica Fischer-Cartlidge Discusses Oral Mucositis Treatment for Patients Taking an mTOR Inhibitor

April 23, 2015
Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS

Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.

Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.

Fischer-Cartlidge says when oral mucositis presents in a patient taking an mTOR inhibitor, it looks and acts differently than oral mucositis in patients receiving chemotherapy.

Fortunately, the oral mucositis in patients taking an mTOR inhibitor responds to steroids better than oral mucositis that presents in patients receiving chemotherapy. The steroid actually healed the oral mucositis instead of just controlling it, Fishcer-Cartlidge says, reducing the need for dose reduction.

<<<

View more from the 40th Annual ONS Congress